Profile data is unavailable for this security.
About the company
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
- Revenue in INR (TTM)49.12bn
- Net income in INR6.59bn
- Incorporated1978
- Employees4.59k
- LocationGland Pharma LtdSurvey No.143-148,150&151Near Gandimaisamma 'X' RoadsD.P Pally, Dundigal Gandimaisamma MandaHYDERABAD 500043IndiaIND
- Phone+91 4 030510999
- Fax+91 4 030510800
- Websitehttps://glandpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Piramal Pharma Ltd | 77.82bn | -333.40m | 161.25bn | 6.30k | -- | -- | 23.18 | 2.07 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 162.91bn | 1.17k | 43.91 | -- | 38.79 | 13.95 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
Natco Pharma Ltd. | 38.28bn | 12.78bn | 174.36bn | 3.98k | 13.74 | -- | 12.02 | 4.55 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
Sanofi India Ltd | 28.51bn | 6.03bn | 183.34bn | 3.53k | 30.41 | 18.06 | 28.54 | 6.43 | 261.78 | 261.78 | 1,237.96 | 440.80 | 1.51 | 2.24 | 21.86 | -- | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.69 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 58.18 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Piramal Enterprises Ltd | 79.98bn | -20.16bn | 187.82bn | 12.22k | -- | -- | -- | 2.35 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
Pfizer Ltd | 22.19bn | 5.02bn | 192.34bn | 1.70k | 38.31 | -- | 33.33 | 8.67 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 193.57bn | 14.59k | 32.80 | -- | 22.08 | 3.16 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
Laurus Labs Ltd | 49.82bn | 1.88bn | 211.38bn | 5.75k | 112.84 | -- | 37.12 | 4.24 | 3.48 | 3.48 | 92.17 | -- | -- | -- | -- | 8,659,934.00 | -- | 11.78 | -- | 19.75 | 51.73 | 48.41 | 4.02 | 14.16 | -- | 2.50 | -- | 12.37 | 22.39 | 23.90 | -4.52 | 36.36 | 20.42 | 31.95 |
J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 254.97bn | 5.10k | 50.34 | -- | 39.62 | 7.53 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 271.59bn | 15.56k | -- | -- | -- | 2.31 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
Ajanta Pharma Ltd | 40.36bn | 7.36bn | 276.20bn | 7.71k | 37.66 | -- | 31.75 | 6.84 | 58.24 | 58.24 | 319.08 | -- | -- | -- | -- | 5,233,334.00 | -- | 16.13 | -- | 19.52 | 74.16 | 74.01 | 18.23 | 19.22 | -- | 100.64 | -- | 15.93 | 12.02 | 11.92 | -17.50 | 4.64 | -7.86 | -- |
Syngene International Ltd | 35.66bn | 5.00bn | 285.31bn | 6.85k | 57.19 | -- | 31.33 | 8.00 | 12.45 | 12.45 | 88.72 | -- | -- | -- | -- | 5,208,267.00 | -- | 8.80 | -- | 11.95 | 71.36 | 70.68 | 14.03 | 17.00 | -- | 6.88 | -- | -- | 22.61 | 17.54 | 17.33 | 8.74 | 7.34 | 0.00 |
Gland Pharma Ltd | 49.12bn | 6.59bn | 299.86bn | 4.59k | 45.53 | -- | 31.62 | 6.10 | 39.98 | 39.98 | 298.11 | -- | -- | -- | -- | 10,713,810.00 | -- | 15.16 | -- | 16.69 | 60.54 | 53.97 | 13.41 | 26.07 | -- | 46.26 | -- | 0.00 | -17.64 | 17.43 | -35.54 | 19.46 | 21.24 | -- |
IPCA Laboratories Ltd | 71.86bn | 5.64bn | 305.79bn | 16.17k | 54.18 | -- | 32.67 | 4.26 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
Biocon Ltd | 146.13bn | 12.00bn | 307.05bn | 3.41k | 25.58 | -- | 10.18 | 2.10 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
GlaxoSmithKline Pharmaceuticals Limited | 33.11bn | 5.29bn | 318.45bn | 3.68k | 60.19 | -- | 53.28 | 9.62 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
Holder | Shares | % Held |
---|---|---|
Mirae Asset Investment Managers (India) Pvt Ltd.as of 29 Feb 2024 | 10.10m | 6.13% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 29 Feb 2024 | 9.05m | 5.50% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 29 Feb 2024 | 4.51m | 2.74% |
UTI Asset Management Co. Ltd. (Investment Management)as of 29 Feb 2024 | 2.20m | 1.34% |
ICICI Prudential Asset Management Co. Ltd.as of 15 Mar 2024 | 1.49m | 0.90% |
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 29 Feb 2024 | 1.31m | 0.80% |
Norges Bank Investment Managementas of 31 Dec 2023 | 1.08m | 0.66% |
Kotak Mahindra Asset Management Co. Ltd.as of 29 Feb 2024 | 882.62k | 0.54% |
Nomura Asset Management Singapore Ltd.as of 26 Oct 2022 | 777.94k | 0.47% |
Invesco Asset Management (India) Pvt Ltd.as of 29 Feb 2024 | 647.30k | 0.39% |